VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ADPT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ADPTAdaptive Biotechnologies Corporation
$28.46$4.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksADPTCash Flow

Adaptive Biotechnologies Corporation (ADPT) Cash Flow Statement

9Y historyFree accessUpdated daily

Free cash flow was positive only in 2025Q4 ($1.4M) and 2026Q3 ($7.7M) against FCF margins swinging from -56.7% to 9.1%, which suggests cash generation remains episodic and largely driven by working capital timing, such as the -$33.9M outflow in 2025Q3.

Income StatementBalance SheetCash FlowRatios

ADPT Cash Flow Statement

Annual statement

ADPT Cash Flow Statement

Adaptive Biotechnologies Corporation (ADPT) cash flow statement — 9-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Cash from Operations-4.28M-45.99M-95.21M-156.32M-183.94M-192.73M-149.68M205.4M-32.26M-34.86M
Operating CF Margin %--16.6%-53.2%-91.81%-99.26%-124.87%-152.14%241.45%-57.95%-90.66%
Operating CF Growth %466.25%51.7%39.09%15.02%4.56%-28.76%-172.87%736.73%7.46%-
Net Income-70.52M-59.5M-159.59M-225.25M-200.19M-207.28M-146.23M-68.61M-46.45M-42.83M
Depreciation & Amortization15.33M17.83M19.26M22.23M20.92M13.95M8.47M7.79M6M5.8M
Stock-Based Compensation46.15M51.48M53.61M00024.76M13.12M11.15M7.01M
Deferred Taxes000000773K-1.88M-1.24M637K
Other Non-Cash Items20.72M1.96M8.97M92.88M66.87M57.41M3.34M43K5K6K
Working Capital Changes-15.76M-57.77M-17.45M-46.18M-71.55M-56.82M-40.8M254.93M-1.72M-5.47M
Change in Receivables-21.85M-8.65M-3.74M2.03M-22.65M-7.36M2.61M-7.82M775K-2.43M
Change in Inventory-275K-998K1.94M-2.84M817K-5.2M-4.99M-1.23M-3.05M-2.7M
Change in Payables-1.28M665K671K-5.41M7.11M3.94M5.25M-2.43M1.87M-1.84M
Cash from Investing-167.65M37.95M77.79M129.65M2.9M181.21M-117.04M-481.7M736K36.43M
Capital Expenditures-4.54M-2.96M-3.66M-10.7M-16.35M-61.75M-18.8M-11.2M-6.32M-2.51M
CapEx % of Revenue1.53%1.07%2.05%6.28%8.82%40.01%19.11%13.17%11.35%6.52%
Acquisitions00000098.24M470.5M19K85K
Investments----------
Other Investing000000-98.24M-470.5M19K122K
Cash from Financing192.52M30.4M241K2.25M132.26M27.15M293.59M319.92M1.25M50.03M
Debt Issued (Net)160.22M000124.38M00000
Equity Issued (Net)18.39M30.4M241K2.25M7.89M26.72M272.16M320.85M049.83M
Dividends Paid0000000000
Share Repurchases-25M000000000
Other Financing13.91M0000429K21.43M-934K1.25M207K
Net Change in Cash20.6M22.37M-17.18M-24.97M-49.03M15.63M26.86M43.62M-30.27M51.61M
Free Cash Flow-8.82M-48.95M-98.88M-167.02M-200.29M-254.47M-168.49M194.2M-38.58M-37.36M
FCF Margin %-2.96%-17.67%-55.25%-98.09%-108.09%-164.87%-171.26%228.28%-69.3%-97.18%
FCF Growth %85.98%50.5%40.8%16.61%21.29%-51.04%-186.76%603.42%-3.25%-
FCF per Share-0.05-0.32-0.67-1.16-1.41-1.81-1.281.56-0.37-0.35
FCF Conversion (FCF/Net Income)0.13x0.77x0.60x0.69x0.92x0.93x1.02x-2.99x0.69x0.81x
Interest Paid-3.58M000000000
Taxes Paid0000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Cash burn and liquidity runway

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Income Swings Diverge From Operating Cash

Based on reported quarterly figures, ADPT's operating cash flow has been consistently less negative than net income across most of the ten quarters, with OCF/NI ratios ranging widely from 0.16 to 3.34, signaling that reported losses are substantially driven by non-cash charges and timing effects rather than pure cash consumption.

The gap between net income and operating cash flow is the central signal in this dataset, and it is not stable enough to be read as a clean earnings-quality measure. The 2026Q3 ratio of 3.34 reflects a $2.9M net income alongside $9.6M of operating cash flow, which suggests working capital and non-cash add-backs such as the $10.4M SBC charge are doing much of the work. Investors should monitor whether this positive divergence persists or reverses once the working capital swing of -$8.0M normalizes.

Free Cash Flow Remains Negative Despite Revenue Growth

According to the reported quarterly figures, ADPT's free cash flow turned positive only in 2025Q4 at $1.4M and in 2026Q3 at $7.7M, with FCF margins swinging from -56.7% to 9.1%, indicating that cash generation remains episodic rather than structural.

The FCF trajectory shows that the business has not yet established consistent cash self-sufficiency, even as the top line expands. Two positive quarters within the last five suggest an inflection is possible but unconfirmed, and the 2026Q2 and 2026Q1 burns of -$7.6M and -$10.3M indicate the prior trend has not fully reversed. Analysts should treat the recent positive FCF as a potential turning point requiring confirmation over additional periods.

Working Capital Volatility Drives Cash Timing

Based on reported figures, working capital changes have ranged from a -$33.9M outflow in 2025Q3 to a $3.1M inflow in 2024Q4, and this volatility appears to account for a large share of the quarter-to-quarter divergence between operating cash flow and earnings.

The magnitude of the 2025Q3 working capital outflow suggests significant receivable build or payables timing, which may have depressed operating cash flow despite a positive $9.5M net income that quarter. Such lumpiness is consistent with milestone-driven and project-based revenue recognition, which can shift collections across periods. Investors should monitor whether the 2026Q3 inflow of positive operating cash reflects genuine collection improvement or a temporary timing benefit.

Minimal Capital Deployment Amid Cash Preservation

As reported in the cash flow statements, ADPT paid no dividends in any period, and buybacks appear only in 2026Q2 at $25.0M, suggesting the company has prioritized liquidity over shareholder returns during this window.

The absence of dividends is unsurprising for a company with persistent negative FCF, but the $25.0M buyback in 2026Q2 is notable given the concurrent negative operating cash flow of -$6.4M and net loss of -$39.8M. This may indicate opportunistic repurchasing or an offset against dilution, and the source of funds warrants further investigation. Such an allocation appears difficult to reconcile with a capital-preservation posture and should be weighed against the company's reported cash position.

Positive Quarters May Not Signal Durable Improvement

Based on reported figures, ADPT's two recent positive FCF quarters rest on a single $9.5M net income period and a $33.9M working capital swing, suggesting that the apparent inflection may reflect timing rather than sustained operating improvement.

Treating the 2026Q3 FCF of $7.7M as evidence of a durable turn overlooks that trailing cumulative free cash flow across the ten quarters remains deeply negative. The SBC add-back of $10.4M contributes materially to operating cash flow, and a substantial portion of reported cash generation may reflect non-cash compensation rather than economic cash earnings. Investors should monitor whether FCF stays positive once working capital normalizes and SBC is treated as a real economic cost.

ADPT — Frequently Asked Questions

Quick answers to the most common questions about buying ADPT stock.

How much cash does Adaptive Biotechnologies Corporation (ADPT) generate from operations?

Adaptive Biotechnologies Corporation (ADPT) generated $-46.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Adaptive Biotechnologies Corporation's free cash flow?

Adaptive Biotechnologies Corporation (ADPT) reported negative free cash flow of $48.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Adaptive Biotechnologies Corporation's capital expenditure (CapEx)?

Adaptive Biotechnologies Corporation (ADPT) spent $3.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.